All-trans-retinoic acid inhibits the growth of human rhabdomyosarcoma cell lines

Gary D. Crouch, Lee J. Helman

Research output: Contribution to journalArticle

Abstract

We have been evaluating the role of all-trans-retinoic acid (RA) in the differentiation and growth of human rhabdomyosarcoma (RMS) cell lines. Treatment of both embryonal (RD) and alveolar (RH30) human RMS cell lines with all-trans-RA resulted in a dose-dependent inhibition of cell growth with a maximal inhibition of 92 and 66%, respectively, at 5 × 10-6 M. When 13-cis-RA was used under identical experimental conditions, maximal growth inhibition was 41 and 37%, respectively. This stereo-specific growth inhibition was not associated with morphological or biochemical evidence of myogenic differentiation. Furthermore, all-trans-RA demonstrated no evidence of competition with binding of insulin-like growth factor II (IGF-II), an autocrine growth factor in RMS, to its membrane receptor as evaluated by an [125I]IGF-I receptor-binding assay. Attempts to rescue all-trans-RA growth-inhibited RMS cells with exogenous IGF-II resulted in no increase in growth compared to cells treated with all-trans-RA alone. We conclude that RA inhibits the growth of human RMS cell lines in a dose-dependent, stereo-specific manner, is not associated with differentiation, and does not appear to be directly related to IGF-II.

Original languageEnglish (US)
Pages (from-to)4882-4887
Number of pages6
JournalCancer Research
Volume51
Issue number18
StatePublished - Sep 15 1991
Externally publishedYes

Fingerprint

Rhabdomyosarcoma
Tretinoin
Cell Line
Growth
Insulin-Like Growth Factor II
Isotretinoin
IGF Type 1 Receptor
Intercellular Signaling Peptides and Proteins
Membranes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

All-trans-retinoic acid inhibits the growth of human rhabdomyosarcoma cell lines. / Crouch, Gary D.; Helman, Lee J.

In: Cancer Research, Vol. 51, No. 18, 15.09.1991, p. 4882-4887.

Research output: Contribution to journalArticle

Crouch, GD & Helman, LJ 1991, 'All-trans-retinoic acid inhibits the growth of human rhabdomyosarcoma cell lines', Cancer Research, vol. 51, no. 18, pp. 4882-4887.
Crouch, Gary D. ; Helman, Lee J. / All-trans-retinoic acid inhibits the growth of human rhabdomyosarcoma cell lines. In: Cancer Research. 1991 ; Vol. 51, No. 18. pp. 4882-4887.
@article{b3022a9dc27a440cb8dbf93581f66ec0,
title = "All-trans-retinoic acid inhibits the growth of human rhabdomyosarcoma cell lines",
abstract = "We have been evaluating the role of all-trans-retinoic acid (RA) in the differentiation and growth of human rhabdomyosarcoma (RMS) cell lines. Treatment of both embryonal (RD) and alveolar (RH30) human RMS cell lines with all-trans-RA resulted in a dose-dependent inhibition of cell growth with a maximal inhibition of 92 and 66{\%}, respectively, at 5 × 10-6 M. When 13-cis-RA was used under identical experimental conditions, maximal growth inhibition was 41 and 37{\%}, respectively. This stereo-specific growth inhibition was not associated with morphological or biochemical evidence of myogenic differentiation. Furthermore, all-trans-RA demonstrated no evidence of competition with binding of insulin-like growth factor II (IGF-II), an autocrine growth factor in RMS, to its membrane receptor as evaluated by an [125I]IGF-I receptor-binding assay. Attempts to rescue all-trans-RA growth-inhibited RMS cells with exogenous IGF-II resulted in no increase in growth compared to cells treated with all-trans-RA alone. We conclude that RA inhibits the growth of human RMS cell lines in a dose-dependent, stereo-specific manner, is not associated with differentiation, and does not appear to be directly related to IGF-II.",
author = "Crouch, {Gary D.} and Helman, {Lee J.}",
year = "1991",
month = "9",
day = "15",
language = "English (US)",
volume = "51",
pages = "4882--4887",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - All-trans-retinoic acid inhibits the growth of human rhabdomyosarcoma cell lines

AU - Crouch, Gary D.

AU - Helman, Lee J.

PY - 1991/9/15

Y1 - 1991/9/15

N2 - We have been evaluating the role of all-trans-retinoic acid (RA) in the differentiation and growth of human rhabdomyosarcoma (RMS) cell lines. Treatment of both embryonal (RD) and alveolar (RH30) human RMS cell lines with all-trans-RA resulted in a dose-dependent inhibition of cell growth with a maximal inhibition of 92 and 66%, respectively, at 5 × 10-6 M. When 13-cis-RA was used under identical experimental conditions, maximal growth inhibition was 41 and 37%, respectively. This stereo-specific growth inhibition was not associated with morphological or biochemical evidence of myogenic differentiation. Furthermore, all-trans-RA demonstrated no evidence of competition with binding of insulin-like growth factor II (IGF-II), an autocrine growth factor in RMS, to its membrane receptor as evaluated by an [125I]IGF-I receptor-binding assay. Attempts to rescue all-trans-RA growth-inhibited RMS cells with exogenous IGF-II resulted in no increase in growth compared to cells treated with all-trans-RA alone. We conclude that RA inhibits the growth of human RMS cell lines in a dose-dependent, stereo-specific manner, is not associated with differentiation, and does not appear to be directly related to IGF-II.

AB - We have been evaluating the role of all-trans-retinoic acid (RA) in the differentiation and growth of human rhabdomyosarcoma (RMS) cell lines. Treatment of both embryonal (RD) and alveolar (RH30) human RMS cell lines with all-trans-RA resulted in a dose-dependent inhibition of cell growth with a maximal inhibition of 92 and 66%, respectively, at 5 × 10-6 M. When 13-cis-RA was used under identical experimental conditions, maximal growth inhibition was 41 and 37%, respectively. This stereo-specific growth inhibition was not associated with morphological or biochemical evidence of myogenic differentiation. Furthermore, all-trans-RA demonstrated no evidence of competition with binding of insulin-like growth factor II (IGF-II), an autocrine growth factor in RMS, to its membrane receptor as evaluated by an [125I]IGF-I receptor-binding assay. Attempts to rescue all-trans-RA growth-inhibited RMS cells with exogenous IGF-II resulted in no increase in growth compared to cells treated with all-trans-RA alone. We conclude that RA inhibits the growth of human RMS cell lines in a dose-dependent, stereo-specific manner, is not associated with differentiation, and does not appear to be directly related to IGF-II.

UR - http://www.scopus.com/inward/record.url?scp=0026425601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026425601&partnerID=8YFLogxK

M3 - Article

C2 - 1893378

AN - SCOPUS:0026425601

VL - 51

SP - 4882

EP - 4887

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 18

ER -